{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"}]}],"title":"Acute GVHD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"48"}]}],"title":"Chronic GVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"Effects of Rituximab as measured by percentage of participants with Acute and Chronic Graft Versus Host Disease (GVHD) incidences after allogeneic transplantation. GVHD occurring anytime after day 90 post transplant was considered chronic GVHD; otherwise it was considered acute GVHD. Acute GVHD status defined as GVHD with maximum grade ≥2. Clinical grading of Acute GVHD (Thomas et al., New England Journal of Medicine (NEJM), 229:895, 1975): Grade 1 to 4.","groups":[{"description":"Fludarabine 30 mg/m\\^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).\n\nMelphalan 140 mg/m\\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\\^2 IV infused starting on day -5.","id":"OG000","title":"Fludarabine + Melphalan + Stem Cell Infusion"},{"description":"Fludarabine 30 mg/m\\^2 IV daily over 30 minutes for 4 Days (Beginning Day -4).\n\nLower-Dose Melphalan 100 mg/m\\^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m\\^2 IV infused starting on day -5.","id":"OG001","title":"Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion"}],"paramType":"NUMBER","populationDescription":"For the acute GVHD analysis, only 48 patients' data were available.","timeFrame":"GVHD grading weekly during first 100 days; Annual examinations for nine year study period","title":"Acute Grade II-IV Graft Versus Host Disease (GVHD)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}